by: Tony Isaacs
(NaturalNews) In the previous installment of this series, we examined the close relationship the American Cancer Society (ACS) has had with the chemical industry. Today we will take a look at the relationships the ACS has had with the Mammography and other industries that profit from cancer.
Why would the ACS, whose mission is supposed to be preventing and finding a cure for cancer, continue to stand so firmly behind the use of mammograms? Perhaps part of the answer comes from the fact that no fewer than five radiologists have served as ACS presidents. In addition, the mammography industry conducts research for the ACS and its grantees, serves on advisory boards, and donates considerable funds.
For example: DuPont, a leading mammography company as well as a leading producer of toxic and carcinogenic chemicals, has been a substantial backer of the ACS Breast Health Awareness Program. DuPont has also sponsored television shows and other media productions touting mammography, produced promotional literature for hospitals, clinics, doctors and medical organizations, produced educational films, and lobbied Congress for legislation promoting the availability of mammography services.
The highly publicized National Breast Cancer Awareness Month campaign further illustrates the conflicts of interest between the ACS and the mammography and other cancer industries. Every October, ACS and NCI representatives help sponsor promotional events, hold interviews, and stress the need for mammography. The flagship of this month-long series of events is the National Breast Cancer Awareness Month organization's sponsored National Mammography Day, which takes place on the third Friday in October. On this day and throughout October radiologists provide free or discounted mammogram screening.
While the country is awash in a sea of pink every year, what is conspicuously absent during Breast Cancer Awareness Month is any information on environmental and other avoidable causes of breast cancer. This has not been by accident. Breast Cancer Awareness Month was created by Imperial Chemicals (now AstraZeneca), which happened to be one of the world's largest manufacturers of chemical carcinogens.
AstraZeneca owns a string of Salick Health Care cancer centers in U. S. hospitals. AstraZeneca subsidiary AstraZeneca Pharmaceuticals is also the manufacturer of tamoxifen, the world's top-selling anticancer and breast cancer "prevention" drug.
In the 1990's, the ACS aggressively launched and promoted a "chemoprevention" program along with the NCI to recruit 16,000 healthy yet supposedly "high risk" women for a 5-year clinical trial with the highly profitable drug tamoxifen. The women were told tamoxifen was essentially harmless and could reduce their risk of breast cancer. They were not told that tamoxifen was a highly potent liver carcinogen in rodent tests or that it was a well-known aggressive human uterine cancer agent
National Breast Cancer Awareness Month is a masterful public relations deception for ACS favorite AstraZeneca as well as other sponsors who either profit from cancer or whose products cause cancer, providing undeserved good will from millions of American women. For an in depth look at the deception involved in National Breast Cancer Awareness Month see:
"Breast Cancer Deception – Hiding the Truth Beneath a Sea of Pink"
In the next installment in this series we will take a look at how the ACS has used their power and influence to suppress and attack alternative cancer treatments that might offer safer and less expensive options than the treatments of the ACS favored companies whose profits would be at risk if such alternatives were accepted.